Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1 Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 35 Lung Neoplasms 13 Neoplasm Metastasis 6 Stomach Neoplasms 3 Thymoma 2 Non-small Cell Lung Cancer Metastatic 2 Biliary Tract Neoplasms 2 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Sarcoma, Alveolar Soft Part 1 Recurrence 1 Mesothelioma, Malignant 1 Mesothelioma 1 Liver Neoplasms 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Hepatocellular 1 Carcinoma 1

Interventions

Pemetrexed 40 Cisplatin 35 pembrolizumab 21 Nivolumab 17 Carboplatin 16 Ipilimumab 13 Gemcitabine 10 Cyclophosphamide 9 fludarabine 6 durvalumab 6 Bevacizumab 6 Radiotherapy, Intensity-Modulated 4 LMB-100 4 Drug Therapy 4 Dexamethasone 4 tremelimumab 3 tazemetostat 3 spartalizumab 3 olaparib 3 niraparib 3 atezolizumab 3 anetumab ravtansine 3 amatuximab 3 Vinorelbine 3 Paclitaxel 3 Oxaliplatin 3 Imatinib Mesylate 3 Fluorouracil 3 Cerebral Decortication 3 Blood Specimen Collection 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Mesothelioma × Ramucirumab × Thoracic × Clear all

NCT03560973 2025-03-13

RAMES

Gruppo Oncologico Italiano di Ricerca Clinica

Phase 2 Completed

Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡